CoGenesis® Cardio-Haema

Cardiovascular and Haematology Medicine

CoGenesis® Cardio-Haema provides recommendations for 12 cardiovascular and haematology medications. It offers you a more personalized approach to select cardiovascular and haematology medications according to your unique genetic makeup.
Order Now Download Brochure


pharmacogenomics-related genes


pharmacogenomics-associated genome variations
Provides recommendations for


cardiovascular and haematology medications
Associated with more than



Who should consider CoGenesis® Cardio-Haema?

  • All cardiovascular and haematology patients
  • Patients who have tried and failed previous treatments
  • Patients who would like to avoid drug side effects
  • Patients who are looking for more personalized medication suggestions

Why CoGenesis® Cardio-Haema?

  • Team of world-class professionals
  • Reader-friendly report
  • Rigorous accuracy and accreditation
  • Updated recommendation guidelines

Genes Tested


Highlighted Implications

Drugs covered in CoGenesis® Cardio-Haema

Agonist of the c-mpl (TpoR) receptor Anti-arrhythmic Anti-coagulant Anti-platelet Treat angina pectoris Antihypertensive Lower lipid

Sample Report

  1. Clinical action for each drug
  2. Individualized genotype and phenotype detections
  3. Implications for detected phenotype
  4. Drug prescription recommendation

The process


Order and receive a saliva collection kit.


Register the sample collection tube barcode online, then take a sample.


Mail the kit back to Codex’s laboratory for analysis.


Results are provided to you securely on the Codex website within six weeks from receipt of sample.

Case Study

An alternative medicine for a different metabolism

It is possible to personalize a drug to avoid known side effects. For example, patients with a SLCO1B1 gene mutation taking simvastatin are more likely to experience a side effect such as muscle weakness. They can undergo genetic testing to optimize their prescription plan, either by lowering the dose or receiving a different statin.

A high accuracy standard

Steps Accuracy
DNA sequencing 99.9%
Variant calling – SNP >99%*#
Variant calling – Indel >99%*#

* Passed GenQA/UK NEQAS external quality assurance

# The interpretation of sequencing variants is based on the current understanding of the variants at the time it was observed, which may change over time as more information about the genes becomes available. Not all variants are represented in this report.

More drug response test services

The interpretations and clinical annotations provided by Codex are intended solely for use by a medical professional and do not constitute medical advice by Codex. Test results shown on this report require clinical interpretation and comments by a specialist of the respective discipline. The pharmacokinetics of a drug might be affected by the dosage form and route of administration. Please consult a qualified healthcare professional before making decisions about medical conditions or before starting and stopping any prescribed treatment. The treating providers are ultimately responsible for all diagnoses and treatments. The report and recommendations are based on the guidelines provided by CPIC1 and do not take into account other genetic variants and environmental or social factors that may affect the drug response. Other factors not included in this report include, but are not limited to, environmental factors (e.g., smoking), health factors (e.g., diet), social factors, various medical conditions, and other concurrent medications. Off-label drug uses are not considered in this report. The recommendations in the report are for the corresponding drugs only, and the drug-drug interactions are not considered. As a matter of practice, Codex will routinely update its database as new information becomes available to the scientific community. Annotations and recommendations are therefore dependent on the date of generation and/or the database version used to generate that report.